Attendance at Treatment Clinical Trial
— SBIRT-PTSDOfficial title:
Evaluation and Treatment of Substance Use in Veterans With PTSD Disability Claims
Verified date | January 2020 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Veterans can apply for compensation and pension (C & P) benefits for a disability related to military service. The application exam for these benefits provides an opportunity for Veterans returning from service to access VA care. The investigators will recruit Veterans applying for C & P to participate in this study. All enrolled participants will complete questionnaires around the time of their C & P exam related to substance abuse, PTSD, service use, and attitudes. The investigators will monitor enrolled Veterans' attendance at treatment over time, and examine whether C & P award, substance use, and beliefs about benefits are related to treatment attendance. Some enrolled participants will be assigned to one of two study groups: a treatment group and a no-additional-treatment group. People assigned to these groups will complete the same substance abuse, PTSD, service use, and attitudes questionnaires two additional times during the study. Participants assigned to the treatment group will receive information about the relationship between substance use and PTSD and will be referred to relevant treatment. The investigators will test whether Veterans who receive no-additional-treatment have different symptoms over time and attend less treatment sessions (mental health or substance abuse) than people assigned to treatment.
Status | Completed |
Enrollment | 346 |
Est. completion date | December 31, 2017 |
Est. primary completion date | September 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Veteran of OEF or OIF, - Not currently receiving VBA Compensation for PTSD, - Able to participate psychologically and physically, able to give informed consent and complete, assessments, and participate in study procedures - Between the ages of 18-65 years old. Exclusion Criteria: - Will not be able to attend the week 4 or 12 appointment because of anticipated incarceration or move |
Country | Name | City | State |
---|---|---|---|
United States | Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Nashville | Tennessee |
United States | VA Connecticut Healthcare System West Haven Campus, West Haven, CT | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development | Yale University |
United States,
Black AC, Meshberg-Cohen S, Perez-Ortiz AC, Thornhill TA, Rosen MI. Veterans' compensation claims beliefs predict timing of PTSD treatment use relative to compensation and pension exam. PLoS One. 2018 Dec 27;13(12):e0209488. doi: 10.1371/journal.pone.0209 — View Citation
Jankowski RL, Black AC, Lazar CM, Brummett BR, Rosen MI. Consideration of substance use in compensation and pension examinations of veterans filing PTSD claims. PLoS One. 2019 Feb 6;14(2):e0210938. doi: 10.1371/journal.pone.0210938. eCollection 2019. — View Citation
Meshberg-Cohen S, Kachadourian L, Black AC, Rosen MI. Relationship between substance use and attitudes towards seeking professional psychological help among veterans filing PTSD claims. Addict Behav. 2017 Nov;74:9-12. doi: 10.1016/j.addbeh.2017.05.024. Ep — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment Attendance by Treatment Group Over Time | Mean number of weeks of substance abuse and/or mental health treatment attended (as measured by the Electronic Medical Record) by treatment group over time | 4 weeks pre-baseline through week 12 post baseline, total of 16 Weeks | |
Secondary | Substance Use by Treatment Group Over Time | Mean days self-reported risky drug or alcohol use | 4 weeks pre-baseline through week 12 post baseline, total of 16 Weeks | |
Secondary | Mean PTSD Severity Score | Measure on Clinical Assessment of PTSD Severity (CAPS IV) rating scale (range 0-136, higher is more severe symptoms). | 12 weeks |